107 related articles for article (PubMed ID: 24097843)
1. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
Hernández-Novoa B; Moreno A; Pérez-Elías MJ; Quereda C; Dronda F; Casado JL; Madrid-Elena N; Aguilar M; Fumero E; Moltó J; Moreno S
J Antimicrob Chemother; 2014 Feb; 69(2):471-5. PubMed ID: 24097843
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
[TBL] [Abstract][Full Text] [Related]
3. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
4. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
Rockstroh J; Teppler H; Zhao J; Sklar P; Harvey C; Strohmaier K; Leavitt R; Nguyen BY
HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.
Milazzo L; Cattaneo D; Calvi E; Gervasoni C; Mazzali C; Ronzi P; Peri AM; Ridolfo AL; D'Avolio A; Antinori S
Int J Antimicrob Agents; 2015 May; 45(5):545-9. PubMed ID: 25769784
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
9. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
10. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of lopinavir in HIV/HCV coinfected patients with advanced liver disease.
Casado JL; Del Palacio M; Moya J; Rodriguez JM; Moreno A; Perez-Elías MJ; Belso A; Dronda F; Moreno S
HIV Clin Trials; 2011; 12(5):235-43. PubMed ID: 22180521
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
Barau C; Braun J; Vincent C; Haim-Boukobza S; Molina JM; Miailhes P; Fournier I; Aboulker JP; Vittecoq D; Duclos-Vallée JC; Taburet AM; Teicher E;
Clin Infect Dis; 2014 Oct; 59(8):1177-84. PubMed ID: 24992955
[TBL] [Abstract][Full Text] [Related]
13. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
[TBL] [Abstract][Full Text] [Related]
15. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
Curran A; Martí R; López RM; Pérez M; Crespo M; Melià MJ; Navarro J; Burgos J; Falcó V; Ocaña I; Ribera E
Antimicrob Agents Chemother; 2015 Nov; 59(11):6782-90. PubMed ID: 26282411
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
[TBL] [Abstract][Full Text] [Related]
17. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
[TBL] [Abstract][Full Text] [Related]
18. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
19. Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C.
Hurt CB; Napravnik S; Moore RD; Eron JJ
Antivir Ther; 2014; 19(4):415-22. PubMed ID: 24458137
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.
Taramasso L; Madeddu G; Ricci E; De Socio GV; Menzaghi B; Orofino G; Passerini S; Franzetti M; Maggi P; Dentone C; Martinelli C; Celesia BM; Penco G; Libertone R; Quirino T; Bonfanti P; Di Biagio A;
Biomed Pharmacother; 2015 Feb; 69():233-6. PubMed ID: 25661363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
